MCP-4, Human, 重组蛋白 (His) TMPY-00564
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | 价格 | 操作 |
---|---|---|
20 μg | ¥1,350.00 | 询底价 |
1 mg | ¥22,400.00 | 询底价 |
100 μg | ¥3,430.00 | 询底价 |
Product Introduction
Bioactivity
英文名: MCP-4 Protein, Human, Recombinant (His)
描述: Monocyte Chemoattractant Proteins 4 (MCP-4/CCL13) is a member of a distinct, structurally-related subclass of CC chemokines mainly involved in recruitment of eosinphils to inflammatory sites. CCL13/MCP-4, is a CC family chemokine that is chemoattractant for eosinophils, basophils, monocytes, macrophages, immature dendritic cells, and T cells, and its capable of inducing crucial immuno-modulatory responses through its effects on epithelial, muscular and endothelial cells. Similar to other CC chemokines, CCL13 binds to several chemokine receptors (CCR1, CCR2 and CCR3), allowing it to elicit different effects on its target cells. A number of studies have shown that CCL13 is involved in many chronic inflammatory diseases, in which it functions as a pivotal molecule involved in the selective recruitment of cell lineages to the inflamed tissues and their subsequent activation. MCP-4/CCL13 is secreted from chondrocytes and activates the proliferation of rheumatoid synovial cells, thereby leading to joint destruction in RA. The interferon-gamma in combination with interleukin-1beta/tumor necrosis factor-alpha activates the production of MCP-4/CCL13 from chondrocytes in RA joints, and that secreted MCP-4/CCL13 enhances fibroblast-like synoviocyte proliferation by activating the extracellular signal-regulated kinase mitogen-activated protein kinase cascade. CCL13 may have some role in the pathogenesis of systemic sclerosis (SSc).
存储条件: Lyophilized powder: -20~-80°C for 1 year | Solution: -80°C for 6~12 month
关键字: SCYL 1 | SCYL-1 | CCL-13 | MCP 4 | CCL 13 | SCYA 13 | NCC 1 | SCYA-13
MCP-4, Human, 重组蛋白 (His) TMPY-00564信息由TargetMol中国为您提供,如您想了解更多关于MCP-4, Human, 重组蛋白 (His) TMPY-00564报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途